Smivet BV is a veterinary biotech company that was founded in 2013 in the Netherlands. The R&D activities came up to speed from end of 2014 onwards. The company decided to focus on the technology of Single Domain Antibodies (SDAs) and develop a suitable supportive SDA platform for use in multiple animal species.

The mission

The mission of the company is to introduce new innovative bio-therapeutics for the treatment of diseased cats, dogs, horses, fish and livestock.

The assets

The company focuses for its internal research pipeline on projects that are based on several proprietary SDA libraries. The even more valuable asset is the knowledge from more than 20 years of experience with R&D and licensing in the veterinary pharmaceutical industry. The R&D of veterinary medicinal products (i.e. Biologicals) is in our genes. The research efforts are supported by a network of specialists from academia and the industry.

The first project reached the stage of proof of concept (POC) in 2019. This product, an in vitro produced Tetanus Antitoxin (De Smit et al. 2021) was fully designed and developed by Smivet and partners. The product can be used in multiple animal species (e.g. horses, cats, dogs and swine). The development of this product is in progress and expected to be commercially available within a few years. The research results have been published as open access science which drives societal progress and advance the United Nations (UN) Sustainable Development Goals (SDGs). The article was linked to SDG 3: Ensure healthy lives and promote well-being for all at all ages.

SDA Libraries

Smivet has next generation sequencing (NGS) data of most of its libraries. The Antibody-ExtractorTM software platform of Abnomx is used to analyse these NGS libraries.

A single-domain antibody (SDA) with its major target binding regions,
the CDR3 region (red), the CDR2 and CDR1 binding regions (yellow).